JP2024520790A5 - - Google Patents
Info
- Publication number
- JP2024520790A5 JP2024520790A5 JP2023575724A JP2023575724A JP2024520790A5 JP 2024520790 A5 JP2024520790 A5 JP 2024520790A5 JP 2023575724 A JP2023575724 A JP 2023575724A JP 2023575724 A JP2023575724 A JP 2023575724A JP 2024520790 A5 JP2024520790 A5 JP 2024520790A5
- Authority
- JP
- Japan
- Prior art keywords
- kallikrein
- sequence
- cells
- nucleotide sequence
- gpi
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163209019P | 2021-06-10 | 2021-06-10 | |
| US63/209,019 | 2021-06-10 | ||
| PCT/IB2022/055355 WO2022259190A1 (en) | 2021-06-10 | 2022-06-08 | Nucleic acid coding for klk2-gpi fusion protein, recombinant cells, and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024520790A JP2024520790A (ja) | 2024-05-24 |
| JP2024520790A5 true JP2024520790A5 (cg-RX-API-DMAC7.html) | 2025-06-11 |
Family
ID=82358484
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023575724A Pending JP2024520790A (ja) | 2021-06-10 | 2022-06-08 | Klk2-gpi融合タンパク質をコードする核酸、組換え細胞、及びその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220403397A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4352217A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024520790A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240021211A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117480253A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022291273A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023025616A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3222756A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL309179A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023014793A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022259190A1 (cg-RX-API-DMAC7.html) |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4873191A (en) | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| GB8901778D0 (en) | 1989-01-27 | 1989-03-15 | Univ Court Of The University O | Manipulatory technique |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| ATE237694T1 (de) | 1991-08-20 | 2003-05-15 | Us Gov Health & Human Serv | Adenovirus vermittelter gentransfer in den gastrointestinaltrakt |
| FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
| US5602299A (en) | 1992-09-23 | 1997-02-11 | Mount Sinai School Of Medicine Of The City University Of New York | Transgenic animal models for neurodegenerative disease |
| EP0673431A1 (en) | 1992-12-03 | 1995-09-27 | Genzyme Corporation | Gene therapy for cystic fibrosis |
| EP0705344B8 (en) | 1993-06-24 | 2006-05-10 | Advec Inc. | Adenovirus vectors for gene therapy |
| US5516639A (en) * | 1993-07-22 | 1996-05-14 | Mayo Foundation For Medical Education And Research | Antibodies specific for human prostate glandular kallkrein |
| DE69435223D1 (de) | 1993-10-25 | 2009-09-03 | Canji Inc | Rekombinanter Adenoviren-Vektor und Verfahren zur Verwendung |
| JPH07132033A (ja) | 1993-11-12 | 1995-05-23 | Hoechst Japan Ltd | アルツハイマー病モデルトランスジェニック動物 |
| US6113917A (en) * | 1995-04-25 | 2000-09-05 | Rmf Dictagene S.A. | Modified polypeptides for enhanced immunogenicity |
| US6066778A (en) | 1996-11-06 | 2000-05-23 | The Regents Of The University Of Michigan | Transgenic mice expressing APC resistant factor V |
| WO2004098529A2 (en) * | 2003-04-30 | 2004-11-18 | Emory University | Therapeutic compositions and vaccines by glycosyl-phosphatidylinositol (gpi)-anchored cytokines and immunostimulatory molecules |
| JP4549666B2 (ja) * | 2003-12-12 | 2010-09-22 | タカラバイオ株式会社 | 抗体の製造方法 |
| ATE440949T1 (de) * | 2004-01-30 | 2009-09-15 | Maxygen Holdings Ltd | Gesteuertes überlesen von stopcodons |
| KR20070084330A (ko) * | 2004-10-18 | 2007-08-24 | 지모제넥틱스, 인코포레이티드 | 가용성 zcytor21, 항-zcytor21 항체 및 결합파트너 및 염증에서의 사용방법 |
| EP2315846A4 (en) * | 2008-08-05 | 2011-11-30 | Univ Rochester | PSA AND KLK2 AS THERAPEUTIC TARGET MOLECULES AND PSA AND KLK2-INHIBITABLE MOLECULES |
| JP6092782B2 (ja) * | 2010-11-16 | 2017-03-08 | エクセリミューン, インコーポレイテッド | 組換えタンパク質の製造方法 |
| EP3218477A4 (en) * | 2014-11-10 | 2018-07-18 | The Board of Trustees of The Leland Stanford Junior University | Compositions and methods for expressing polypeptides on the surface of cells |
| TW202118792A (zh) * | 2019-07-26 | 2021-05-16 | 美商健生生物科技公司 | 抗hk2嵌合抗原受體(car) |
-
2022
- 2022-06-08 WO PCT/IB2022/055355 patent/WO2022259190A1/en not_active Ceased
- 2022-06-08 EP EP22735984.1A patent/EP4352217A1/en active Pending
- 2022-06-08 IL IL309179A patent/IL309179A/en unknown
- 2022-06-08 KR KR1020247000497A patent/KR20240021211A/ko active Pending
- 2022-06-08 JP JP2023575724A patent/JP2024520790A/ja active Pending
- 2022-06-08 AU AU2022291273A patent/AU2022291273A1/en active Pending
- 2022-06-08 US US17/835,671 patent/US20220403397A1/en active Pending
- 2022-06-08 MX MX2023014793A patent/MX2023014793A/es unknown
- 2022-06-08 BR BR112023025616A patent/BR112023025616A2/pt not_active Application Discontinuation
- 2022-06-08 CA CA3222756A patent/CA3222756A1/en active Pending
- 2022-06-08 CN CN202280041004.7A patent/CN117480253A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2625316T3 (es) | Neuquinasa, una proteína corriente abajo de neuregulina | |
| RU2577971C2 (ru) | Система для увеличения экспрессии генов и вектор, содержащий указанную систему | |
| JP5264518B2 (ja) | マルチマータンパク質およびマルチマータンパク質を作製および使用する方法 | |
| ES2271004T3 (es) | Uso de taci como agente antitumoral. | |
| JP7770368B2 (ja) | ヒト化asgr1座位を含む非ヒト動物 | |
| JP4500541B2 (ja) | ウイルスコートタンパク質/受容体キメラおよび使用方法 | |
| US20200085871A1 (en) | Methods of using cytotoxic t cells for treatment of autoimmune diseases | |
| US8993742B2 (en) | Tubulo-vesicular structure localization signals | |
| AU1162100A (en) | Method for producing antibodies acting against a polypeptide that only recognises the coding nucleic acid | |
| CN110799530A (zh) | Hla-g转录物和同种型及它们的用途 | |
| JP2023546156A (ja) | Hivを標的にするwwドメイン活性化細胞外ベシクル | |
| JPWO2006035741A1 (ja) | Es細胞特異的発現遺伝子及びその利用 | |
| Drewlo et al. | C-Terminal truncations of syncytin-1 (ERVWE1 envelope) that increase its fusogenicity. | |
| US8318662B2 (en) | Protein increasing cell infectivity of herpes simplex virus and use thereof | |
| FI3687287T3 (fi) | Humanisoitua c1q-kompleksia ilmentävät jyrsijät | |
| ES2284532T3 (es) | Quimeras de proteina de envuelta viral/receptor y metodos de uso. | |
| US20220403397A1 (en) | Nucleic acid constructs encoding kallikrein-2 fusion protein and vectors, preparations of cells, and methods of use thereof | |
| US20260053122A1 (en) | Transgenic animals expressing chimeric c-kit protein | |
| US20250352618A1 (en) | Methods of treating bronchopulmonary dysplasia | |
| JP2008283882A (ja) | タグ抗体発現トランスジェニック非ヒト動物およびタグ付与型アデノウイルスベクターによる遺伝子導入方法 | |
| JP2001519180A (ja) | ラミニン及びそれらの利用 | |
| Miyagawa et al. | A synthetic DAF (CD55) gene based on optimal codon usage for transgenic animals | |
| KR101389088B1 (ko) | 염기서열 최적화된 나트륨-요오드 수송체 유전자 및 그 용도 | |
| NZ783284B2 (en) | Modified adenoviruses | |
| US20040235769A1 (en) | Anti-tumor effects of prostage Carcinoma Tumor Antigen-1 |